Bestatin is a reversible, competitive metalloprotease inhibitor that selectively inhibits aminopeptidases such as triamino peptidase, Aminopeptidase B at 60 nM (using arginine-β-naphthylamide as substrate), Aminopeptidase M (CD13), and leucine aminopeptidase (LAP3) at 20 nM (leucine-β-naphthylamide as substrate), while displaying no inhibition of aminopeptidase A, trypsin, chymotrypsin, elastase, papain, pepsin, or themolysin.
It is also a potent inhibitor of leukotriene A4 hydrolase (LTA4), potentially allowing investigation of the role of LTA4 in inflammation.
It offers promise as a novel analgesic since it protects endogenous opioid peptides against degradation and exhibits anti-angiogenic properties while inhibiting new blood vessel formation at the early stages of tumor growth as well as at the metastatic sites.
Bestatin has been used as a protease inhibitor for the purification of his-tagged Tau protein.
Storage: After reconstitution, aliquot in smaller volumes and freeze (-20°C). Stock solutions in DMSO and methanol are stable for up to 1 month at -20°C.